Frazor Titus Edmondson III Sells 14,544 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Frazor Titus Edmondson III sold 14,544 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $32.98, for a total transaction of $479,661.12. Following the completion of the sale, the insider now directly owns 14,328 shares of the company’s stock, valued at approximately $472,537.44. This trade represents a 50.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zai Lab Price Performance

ZLAB opened at $35.91 on Thursday. Zai Lab Limited has a fifty-two week low of $13.48 and a fifty-two week high of $36.60. The company has a market capitalization of $3.93 billion, a P/E ratio of -12.96 and a beta of 1.02. The firm’s fifty day moving average price is $27.92 and its two-hundred day moving average price is $26.18.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. The business had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. On average, equities research analysts expect that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Zai Lab

Large investors have recently modified their holdings of the stock. FMR LLC lifted its position in shares of Zai Lab by 749.1% during the 4th quarter. FMR LLC now owns 5,475,505 shares of the company’s stock worth $143,403,000 after buying an additional 4,830,646 shares during the period. RTW Investments LP acquired a new position in Zai Lab during the fourth quarter worth $65,714,000. Janus Henderson Group PLC lifted its holdings in shares of Zai Lab by 34.2% during the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after acquiring an additional 2,232,507 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Zai Lab in the 4th quarter valued at $46,172,000. Finally, Wellington Management Group LLP grew its holdings in shares of Zai Lab by 18.4% in the 3rd quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company’s stock worth $203,660,000 after purchasing an additional 1,312,115 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald upgraded shares of Zai Lab to a “strong-buy” rating in a research note on Tuesday. Bank of America reaffirmed a “neutral” rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a report on Monday.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.